{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:56:59Z","timestamp":1764277019630,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12325-020-01426-7","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T09:08:02Z","timestamp":1594285682000},"page":"3791-3806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.1007","volume":"37","author":[{"given":"Ali","family":"Tafazzoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameya","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Harty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorgen","family":"Moller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schiffon L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"issue":"3","key":"1426_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"issue":"3","key":"1426_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2174\/157015911796557911","volume":"9","author":"I Loma","year":"2011","unstructured":"Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9(3):409\u201316.","journal-title":"Curr Neuropharmacol"},{"issue":"10130","key":"1426_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, et al. Multiple sclerosis. Lancet. 2018;391(10130):1622\u201336.","journal-title":"Lancet"},{"issue":"5","key":"1426_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/1756285615598910","volume":"8","author":"RS Farber","year":"2015","unstructured":"Farber RS, Sand IK. Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord. 2015;8(5):212\u201332.","journal-title":"Ther Adv Neurol Disord"},{"key":"1426_CR5","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9:S5\u2013S48.","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"1426_CR6","first-page":"844","volume":"23","author":"KM Johnson","year":"2017","unstructured":"Johnson KM, et al. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm. 2017;23(8):844\u201352.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1426_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273\u20139.","journal-title":"Pract Neurol"},{"issue":"8","key":"1426_CR8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/ene.13632","volume":"25","author":"I Corbelli","year":"2018","unstructured":"Corbelli I, et al. Early management of patients with medication-overuse headache: results from a multicentre clinical study. Eur J Neurol. 2018;25(8):1027\u201333.","journal-title":"Eur J Neurol"},{"issue":"8","key":"1426_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ene.13657","volume":"25","author":"AP Andreou","year":"2018","unstructured":"Andreou AP, et al. Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. Eur J Neurol. 2018;25(8):1069\u2013e83.","journal-title":"Eur J Neurol"},{"key":"1426_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","volume":"29","author":"R McCool","year":"2019","unstructured":"McCool R, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:55\u201361.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"1426_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.rdc.2018.09.012","volume":"45","author":"KM Mullen","year":"2019","unstructured":"Mullen KM. Challenges in having an infusion center. Rheum Dis Clin North Am. 2019;45(1):87\u2013100.","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"1426_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.7224\/1537-2073-13.2.95","volume":"13","author":"JF Foley","year":"2011","unstructured":"Foley JF, Dunne AM. Successful management of a neurology infusion practice. Int J MS Care. 2011;13(2):95\u2013104.","journal-title":"Int J MS Care"},{"issue":"3","key":"1426_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist TP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257\u201367.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1426_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"issue":"8","key":"1426_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1080\/03007995.2019.1585779","volume":"35","author":"A Berardi","year":"2019","unstructured":"Berardi A, et al. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches. Curr Med Res Opin. 2019;35(8):1371\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1426_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","volume":"34","author":"MK Siddiqui","year":"2017","unstructured":"Siddiqui MK, et al. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing\u2013remitting multiple sclerosis. Curr Med Res Opin. 2017;34(8):1361\u201371.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1426_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","volume":"21","author":"R Hettle","year":"2018","unstructured":"Hettle R, Harty G, Wong SL. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. J Med Econ. 2018;21(7):676\u201386.","journal-title":"J Med Econ"},{"key":"1426_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.msard.2017.10.002","volume":"18","author":"T Eagle","year":"2017","unstructured":"Eagle T, et al. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017;18:196\u2013201.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1426_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/0272989X19897944","volume":"40","author":"MF Jonker","year":"2020","unstructured":"Jonker MF, et al. Summarizing patients\u2019 preferences for the competitive landscape of multiple sclerosis treatment options. Med Decis Mak. 2020;40(2):198\u2013211.","journal-title":"Med Decis Mak"},{"issue":"7","key":"1426_CR20","first-page":"18","volume":"3","author":"K Rosenburg","year":"2010","unstructured":"Rosenburg K. Split scheduling for chemotherapy increases efficiency, reduces costs. J Multidiscip Cancer Care. 2010;3(7):18\u20139.","journal-title":"J Multidiscip Cancer Care"},{"issue":"12","key":"1426_CR21","first-page":"541","volume":"38","author":"P Santib\u00e1\u00f1ez","year":"2012","unstructured":"Santib\u00e1\u00f1ez P, et al. Operations research methods improve chemotherapy patient appointment scheduling. Jt Comm J Qual Patient Saf. 2012;38(12):541\u201353.","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"2","key":"1426_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/0037549717708246","volume":"94","author":"MM Alvarado","year":"2017","unstructured":"Alvarado MM, et al. Modeling and simulation of oncology clinic operations in discrete event system specification. Simulation. 2017;94(2):105\u201321.","journal-title":"Simulation"},{"issue":"10","key":"1426_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4066\/AMJ.2011.837","volume":"4","author":"Z Ahmed","year":"2011","unstructured":"Ahmed Z, Elmekkawy T, Bates S. Developing an efficient scheduling template of a chemotherapy treatment unit: a case study. Aust Med J. 2011;4(10):575\u201388.","journal-title":"Aust Med J"},{"issue":"1","key":"1426_CR24","doi-asserted-by":"publisher","first-page":"1400857","DOI":"10.1080\/21614083.2017.1400857","volume":"6","author":"ML Van Driel","year":"2017","unstructured":"Van Driel ML, et al. Learnings and challenges to deploy an interprofessional and independent medical education programme to a new audience. J Eur CME. 2017;6(1):1400857.","journal-title":"J Eur CME"},{"issue":"9","key":"1426_CR25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/ene.13674","volume":"25","author":"ES Kristoffersen","year":"2018","unstructured":"Kristoffersen ES, et al. Medication-overuse headache detoxification reduces headache disability\u2014the Akershus study of chronic headache. Eur J Neurol. 2018;25(9):1140\u20137.","journal-title":"Eur J Neurol"},{"issue":"2","key":"1426_CR26","first-page":"158","volume":"40","author":"ZY Chen","year":"2018","unstructured":"Chen ZY, et al. Altered brainstem volume in medication-overuse headache: a pilot magnetic resonance imaging evaluation. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018;40(2):158\u201362.","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"1426_CR27","volume-title":"Monitoring burden of multiple sclerosis (MS) treatment in the UK: feasibility phase for an observations time and motion (T&M) study","author":"E De Cock","year":"2018","unstructured":"De Cock E, et al. Monitoring burden of multiple sclerosis (MS) treatment in the UK: feasibility phase for an observations time and motion (T&M) study. Baltimore: ISPOR; 2018."},{"issue":"4","key":"1426_CR28","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00296-010-1647-3","volume":"32","author":"K Athanasakis","year":"2012","unstructured":"Athanasakis K, et al. Greek NHS capacity constraints regarding intravenous treatment for rheumatoid arthritis patients. Rheumatol Int. 2012;32(4):921\u20136.","journal-title":"Rheumatol Int"},{"key":"1426_CR29","unstructured":"Royal College of Physicians. Underfunded. Underdoctored. Overstretched. The NHS in 2016. London: Royal College of Physicians; 2016."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01426-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01426-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01426-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:55:55Z","timestamp":1625788555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01426-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01426-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"3 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}